|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122395 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-13 16:20:34 |
|
注册时间: Date of Registration: |
2026-04-13 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
前交叉韧带重建患者运动恐惧康复管理试验 |
|
Public title: |
A Trial of Kinesiophobia Rehabilitation Management in Patients Undergoing Anterior Cruciate Ligament Reconstruction |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于COM-B模型的早期运动管理方案在前交叉韧带重建患者中的应用研究 |
|
Scientific title: |
Application of an Early Exercise Management Program Based on the COM-B Model in Patients Undergoing Anterior Cruciate Ligament Reconstruction |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
徐晓娜 |
研究负责人: |
孙月荣 |
|
Applicant: |
Xu Xiaona |
Study leader: |
Sun Yuerong |
|
申请注册联系人电话: Applicant telephone: |
+86 199 5323 2239 |
研究负责人电话:
Study leader's |
+86 186 6180 5211 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1073040292@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
18661805211@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省青岛市崂山区海尔路59号 |
研究负责人通讯地址: |
山东省青岛市崂山区海尔路59号 |
|
Applicant address: |
No. 59 Haier Road, Laoshan District, Qingdao, Shandong Province, China |
Study leader's address: |
No. 59 Haier Road, Laoshan District, Qingdao, Shandong Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
青岛大学附属医院 |
||
|
Applicant's institution: |
The Affiliated Hospital of Qingdao University |
||
|
研究负责人所在单位: |
青岛大学附属医院 |
||
|
Affiliation of the Leader: |
The Affiliated Hospital of Qingdao University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
QYFY WZLL 30057 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
青岛大学附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Medical Ethics Committee of the Affiliated Hospital of Qingdao University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-31 00:00:00 | ||
|
伦理委员会联系人: |
刘奕辰 |
||
|
Contact Name of the ethic committee: |
Liu Yichen |
||
|
伦理委员会联系地址: |
山东省青岛市市南区江苏路16号 |
||
|
Contact Address of the ethic committee: |
No. 16 Jiangsu Road, Shinan District, Qingdao, Shandong Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 186 6180 2841 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
青岛大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated Hospital of Qingdao University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省青岛市崂山区海尔路59号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 59 Haier Road, Laoshan District, Qingdao, Shandong Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自付 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-paying |
||||||||||||||||||||||
|
研究疾病: |
前交叉韧带损伤 |
||||||||||||||||||||||
|
Target disease: |
Anterior Cruciate Ligament Injury |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过文献分析及质性访谈归纳ACLR患者运动恐惧的促进因素与障碍因素,构建基于同理心地图与COMB模型的ACLR患者运动恐惧康复管理方案,探讨该干预方案在降低运动恐惧程度、提高功能锻炼依从性、改善膝关节功能及康复自我效能等方面的效果,判断方案的科学可行性。 |
||||||||||||||||||||||
|
Objectives of Study: |
Through literature analysis and qualitative interviews, this study aims to identify the facilitating factors and barriers associated with kinesiophobia in patients undergoing Anterior Cruciate Ligament Reconstruction (ACLR). Based on these findings, a rehabilitation management program for ACLR patients with kinesiophobia will be developed, structured around the Empathy Map and the COM-B model. The study will then investigate the effectiveness of this intervention program in reducing the degree of kinesiophobia, improving compliance with functional exercises, enhancing knee joint function, and boosting rehabilitation self-efficacy, ultimately determining the scientific feasibility of the proposed protocol. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.入院择期行前交叉韧带重建(ACLR)患者; 2.年龄18~50岁; 3.入院Tampa恐动症(TSK)评分>37分; 4.精神正常能够正常沟通; 5.自愿参加且签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients admitted for elective anterior cruciate ligament reconstruction (ACLR); 2. Aged 18–50 years; 3. Tampa Scale of Kinesiophobia (TSK) score > 37 at admission; 4. Mentally normal and able to communicate effectively; 5. Voluntarily participate and sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.此次合并后交叉韧带/侧副韧带/半月板损伤/骨折手术; 2.既往关节手术史; 3.合并下肢静脉血栓; 4.正在参与其他研究; 5.未按计划行ACLR患者; 6.要求退出研究或失访。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Combined posterior cruciate ligament (PCL) / collateral ligament / meniscus injury / fracture surgery; 2. History of previous joint surgery; 3. Combined with lower extremity venous thrombosis; 4. Currently participating in other studies; 5. Patients who did not undergo ACLR as planned; 6. Request to withdraw from the study or are lost to follow-up. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-05-06 00:00:00 至 To 2025-07-28 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
设置一个区组长度为4的区组,包含2个A(试验组)和2个B(对照组),产生6种排列方式,使用统计软件SPSS生成20个随机数(对应20个区组),将这20个随机数按从小到大排序,根据顺序从6种排列中依次抽取一个排列方式,作为第1个区组、第2个区组……直至第20个区组的入组顺序。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A block with a length of 4 was set, containing 2 A's (experimental group) and 2 B's (control group), resulting in 6 possible permutations. The statistical software SPSS was used to generate 20 random numbers (corresponding to 20 blocks). These 20 random numbers were sorted in ascending order. Based on this order, one permutation was sequentially drawn from the 6 permutations as the allocation sequence for the 1st block, the 2nd block, and so on, up to the 20th block. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲(入组患者不知晓自己属于试验组还是对照组,医护人员知晓入组患者属于试验组还是对照组) |
|
Blinding: |
Single-blind (The enrolled patients are unaware of whether they belong to the experimental group or the control group, while the medical staff are aware of the group assignment of the enrolled patients). |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2026.06.15 通过临床试验公共管理平台ResMan(www.medresman.org)共享数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data is scheduled to be shared on June 15, 2026 by Clinical Trial Public Management Platform(ResMan):www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集使用电子CRF,确保涵盖患者基本信息及测量指标等,将严格遵守数据与原始病历一致;数据管理采用ResMan平台管理数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection will be conducted using an electronic CRF to ensure coverage of basic patient information and measurement indicators, with strict adherence to maintaining consistency with the original medical records. Data management will be performed using the ResMan platform. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |